Boston Scientific (NYSE:BSX) Reaches New 1-Year Low After Analyst Downgrade

Shares of Boston Scientific Corporation (NYSE:BSX) reached a new 52-week low during mid-day trading on Tuesday after Citigroup lowered their price target on the stock from $94.00 to $87.00. Citigroup currently has a buy rating on the stock. Boston Scientific traded as low as $61.09 and last traded at $60.9870, with a volume of 3119408 shares trading hands. The stock had previously closed at $62.59.

A number of other research firms have also issued reports on BSX. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Truist Financial dropped their price objective on shares of Boston Scientific from $95.00 to $92.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a research note on Monday, February 2nd. Royal Bank Of Canada reiterated an “outperform” rating and issued a $115.00 price objective on shares of Boston Scientific in a research note on Monday, March 30th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $97.00 price objective on shares of Boston Scientific in a research note on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $104.05.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.50% of the stock is currently owned by company insiders.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Leerink reiterated an Outperform after the CHAMPION‑AF readout met primary safety and efficacy endpoints, giving clinical validation that supports BSX’s growth outlook. Leerink Reiterates Outperform on Boston Scientific After CHAMPION-AF Readout
• Neutral Sentiment: Market commentary notes the stock ticked up in a recent session but continues to underperform broader markets, suggesting short‑term volatility rather than a clear directional reversal. Boston Scientific Corp. stock rises Wednesday, still underperforms market
• Neutral Sentiment: Value/entry‑call pieces ask whether the recent sharp pullback makes BSX attractive, highlighting the stock’s steep YTD and 1‑year declines and raising valuation questions for long‑term investors. Is It Time To Revisit Boston Scientific After This Year’s Sharp Share Price Pullback
• Neutral Sentiment: Erste Group marginally trimmed its FY26 EPS forecast (from $3.46 to $3.45), a small technical change but part of broader analyst estimate revisions investors should monitor. MarketBeat / Analyst Note (Erste Group)
• Negative Sentiment: Citigroup lowered its price target on BSX from $94 to $87 while keeping a Buy rating, signaling reduced near‑term upside expectations and contributing to downside pressure. Citigroup Lowers Price Target on Boston Scientific
• Negative Sentiment: AmericanBankingNews reported Citi has lowered expectations for BSX stock price, reinforcing the message of reduced analyst upside. Citigroup Has Lowered Expectations for Boston Scientific
• Negative Sentiment: Multiple law firms and plaintiff notices (Robbins Geller, Pomerantz, Rosen, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Bragar Eagel & Squire, Bernstein Liebhard) have issued class‑action reminders and investor alerts covering purchasers from July 23, 2025 to Feb 3, 2026 — increasing litigation visibility and potential future financial/legal costs. Robbins Geller Class Action Notice
• Negative Sentiment: Pomerantz LLP and other firms echoed class‑action filings/alerts, which can prolong headline risk and amplify short‑term selling pressure as investors price in potential settlements or legal expenses. Pomerantz Investor Alert
• Negative Sentiment: Additional firm notices (Bronstein, Faruqi, Bragar, Bernstein Liebhard, Rosen) set a May 4 lead‑plaintiff deadline — watch for consolidation of claims and any company responses. Bernstein Liebhard Deadline Alert
• Negative Sentiment: Kahn Swick & Foti opened an investigation into the proposed Penumbra sale structure (BSX offer involves cash or shares), which could introduce M&A process scrutiny and potential deal uncertainty. Penumbra Investor Alert re: BSX Deal

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Steph & Co. acquired a new position in Boston Scientific in the 3rd quarter valued at $25,000. Financial Consulate Inc. acquired a new position in Boston Scientific in the 3rd quarter valued at $25,000. Murphy & Mullick Capital Management Corp grew its stake in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter valued at $26,000. Finally, Swiss RE Ltd. acquired a new position in Boston Scientific in the 4th quarter valued at $26,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Down 2.0%

The business’s 50 day moving average is $72.73 and its 200-day moving average is $88.57. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The firm has a market capitalization of $91.10 billion, a price-to-earnings ratio of 31.60, a price-to-earnings-growth ratio of 0.97 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the business posted $0.70 EPS. Boston Scientific’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.